Nicholas Investment Partners’s Apogee Therapeutics APGE Stock Holding History

Nicholas Investment Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-130,992	Closed	-$11M	–	209
2026 Q1	$11M	Buy	130,992 +18,068	+16%	+$1.31M	0.8%	39
2025 Q4	$8.52M	Buy	+112,924	New	+$7.11M	0.62%	61
2024 Q2	–	Sell	-37,747	Closed	-$2.51M	–	198
2024 Q1	$2.51M	Buy	+37,747	New	+$1.65M	0.26%	138

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Nicholas Investment Partners's APGE Position: Q2 2026 in Review

Nicholas Investment Partners sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 130,992 shares — an estimated $11M sold.

Nicholas Investment Partners first reported a position in APGE in Q1 2024 and held it in 3 quarters. The position peaked at $11M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Nicholas Investment Partners reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
Nicholas Investment Partners sold 130,992 Apogee Therapeutics shares in Q2 2026, an estimated $11M.
Nicholas Investment Partners first reported a position in Apogee Therapeutics in Q1 2024 and held it in 3 quarters.
Nicholas Investment Partners's Apogee Therapeutics position peaked at $11M in Q1 2026.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.